HILLEVAX INC (HLVX) Stock News
NASDAQ:HLVX - Nasdaq - US43157M1027 - Common Stock - Currency: USD
HLVX Latest News, Press Relases and Analysis
HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
$159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development...
HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress
$171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for continued...
HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress
HLVX Stock Earnings: HilleVax Misses EPS for Q2 2024
HLVX stock results show that HilleVax missed analyst estimates for earnings per share the second quarter of 2024.
HilleVax Announces Reduction in Force
BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and...
HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
$189.3 million of cash, cash equivalents and marketable securities as of September 30, 2024 The company is exploring the potential for continued...
HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ: HLVX). Such investors are...
HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of...
HLVX Stock Earnings: HilleVax Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips HilleVax (NASDAQ:HLVX) just reported results for the first quarter of 2024.Hill...
HLVX Stock Earnings: HilleVax Misses EPS for Q1 2024
HLVX stock results show that HilleVax missed analyst estimates for earnings per share the first quarter of 2024.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ: HLVX). Such investors are...
HilleVax Announces Reduction in Force
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ: HLVX). Such investors are...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ: HLVX). Such investors are...
HilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
HLVX Stock Earnings: HilleVax Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips HilleVax (NASDAQ:HLVX) just reported results for the fourth quarter of 2023.Hil...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ: HLVX). Such investors are...
HilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
GRFS Stock Alert: Grifols Pops 20% on Takeover Interest
Grifols stock is up on Monday as the founding family of the company has presented a preliminary takeover offer for GRFS shares.
Why Is HilleVax (HLVX) Stock Down 87% Today?
HilleVax stock is down on Monday after HLVX investors learned of a failed Phase 2b clinical trial of its norovirus vaccine for infants.
HLVX Investors Have Opportunity to Join HilleVax, Inc. Securities Fraud Investigation with the Schall Law Firm
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
The NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will discontinue further development of HIL-214 in...
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants